LMB 9

Drug Profile

LMB 9

Alternative Names: B3ds(Fv)-PE38; NSC 691236

Latest Information Update: 28 Mar 2007

Price : $50

At a glance

  • Originator Battelle Memorial Institute; National Cancer Institute (USA)
  • Class Antineoplastics; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Colorectal cancer; Gastric cancer; Gastrointestinal cancer; Pancreatic cancer; Solid tumours

Most Recent Events

  • 27 Jan 2006 IVAX Corporation has been acquired by Teva Pharmaceutical Industries
  • 23 Oct 2003 Phase-I clinical trials in Gastrointestinal cancer in USA (IV-infusion)
  • 23 Oct 2003 Phase-I clinical trials in Pancreatic cancer in USA (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top